Telomir Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $63.27M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Telomir Pharmaceuticals has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Telomir Pharmaceuticals filed with the SEC
Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Pricing of Initial Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Announces Closing of Initial Public Offering
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K